Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.

Abstract: Use of a composition which contains at least one semifluorinated alkane compound and at least one liquid siloxane, wherein the composition is of a density in a range of 0.8 to 1.5 g/cm3, for preserving organs or limbs.

Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.

Abstract: Use of a composition which contains at least one semifluorinated alkane compound and at least one liquid siloxane, wherein the composition is of a density in a range of 0.8 to 1.5 g/cm3, for preserving organs or limbs.

Abstract: Use of a biocompatible dye, for example patent blue V or brilliant blue R, for the production of a dye agent for non-cytotoxic visualisation of cells, in particular delimiting or separating membranes in the human or animal body, in particular in the eye.

Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.

Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.

Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.

Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.

Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH and RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.

Abstract: Described is a method for the purification of perfluorocarbons, or mixtures of perfluorocarbons, having impurities containing hydrogen and/or carbon-carbon double bonds. The impure perfluorocarbons or perfluorocarbon mixtures are reacted with strong aqueous bases in the presence of Ca.sup.2+ or Ba.sup.2+ ions and alcoholate ions together with secondary amines.

Abstract: A vitreous humor tamponade for the posterior cavity in an eye, including at least one perfluorocarbon which is liquid under normal conditions and which after injection in the eye changes into the vapor condition as a result of its vapor pressure.

Abstract: A treatment agent for ophthalmology comprising a liquid perfluorinated compound (modified perfluorcarbon) of one of the types: ##STR1##

Abstract: A treatment liquid for unfolding detached retina to the chorioid of the eye containing a PFC-mixture whose PFCs are free from C.dbd.C-double bonds and C--H-bonds, with a reduced vapor pressure and a refractive index by virtue of which the PFC/tissue fluid interface is made visible.

Abstract: A process for separation of mixtures of partially- or perfluorinated hydrocarbon compounds, which optionally contain additional chain members from the heteroatom group nitrogen, oxygen, boron, phosphorus and sulfur and/or can be substituted by further halogen atoms, characterized in that such partially- or perfluorinated compounds, which have an acyclic straight-chain structure and a critical molecule diameter in the range from 4 to 7 .ANG. or are substituted by residues with a straight-chain acyclic structure and with a critical molecule diameter in the range from 4 to 7 .ANG., of such partially- or perfluorinated compounds, which have no straight-chain acyclic residues, and whose critical molecule diameter amounts to at least 1.

Abstract: A diluent for perfluorocarbons used for retinal unfolding (unfolding PFCL), consisting of a perfluorocarbon (diluent PFCL), which has a low viscosity and is volatile at room temperature, with a boiling point between body temperature (about 38.degree. C.) and 100.degree. C., for removing residual quantities of unfolding PFCL from the eye after performance of a retinal unfolding treatment. A method of treatment consisting of introducing into an eye the above diluent for the above purpose.

Abstract: A method for preparing perfluorinated heterocyclic compounds corresponding to the formulas Ia and Ib ##STR1## wherein m represents 3 or 4, andX is a --CF.sub.2 --O--CF.sub.2 -- group, a --CF.sub.2 --CF.sub.2 --CF.sub.2 -- group, or a --CF(CF.sub.3)--CF.sub.2 -- group,and their mixtures, and the perfluoro-N-cyclohexylmorpholine prepared by this method. The compounds are obtained by electrochemical perfluorination starting from corresponding cycloalkenyl derivatives, and they can be used for preparing medically usable aqueous emulsions, e.g. blood substitutes.

Abstract: The use of perfluorinated heterocyclic compounds of the general formula I, ##STR1## wherein n represents 2-8,X and Y represent a --CF.sub.2 OCF.sub.2 -- group, a --CF.sub.2 --CF.sub.2 --CF.sub.2 -- group or a --CF(CF.sub.3)--CF.sub.2 -- group, andY is a --CF.sub.2 --O--CF.sub.2 -- group, a --CF(CF.sub.3)--CF.sub.2 -- group or a --CF.sub.2 --CF.sub.2 --CF.sub.2 -- group,or mixtures thereof, is described as emulsion-stabilizing additives in medically usable aqueous emulsions of perfluorocarbons, optionally containing hetero atoms, suitable for use in blood substitutes. The compounds are obtained by electrochemical perfluorination.

Abstract: A method for preparing perfluorinated heterocyclic compounds corresponding to the formulas Ia and Ib ##STR1## wherein m represents 3 or 4, andx is a --CF.sub.2 --O--CF.sub.2 -- group, a --CF.sub.2 --CF.sub.2 --CF.sub.2 -- group, or a --CF(CF.sub.3)--CF.sub.2 -- group,and their mixtures, and the perfluoro-N-cyclohexylmorpholine prepared by this method. The compounds are obtained by electrochemical perfluorination starting from corresponding cycloalkenyl derivatives, and they can be used for preparing medically usable aqueous emulsions, e.g. blood substitutes.